110414 renal pharm Flashcards

(45 cards)

1
Q

high incidence of acute kidney injury occurs in what cases?

A

in pts receiving antibiotics, chemo, or radiocontrast dyes

common complication also of thoracic surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

mechanism of acute kidney injury

A

arterial occlusion, hypotension, shock

renal ischemia-reperfusion

microvascular dysfxn
excess vasoconstriction
inflam, oxidative stress
endothelial injury
endothelial-leukocyte interactions

mismatch btwn O2 consumption and O2 supply

renal tissue hypoxia

tubular necrosis and apoptosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

most common causes of chronic kidney disease

A

diabetic nephropathy

HTN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

tx for chronic kidney disease

A

inhibitors of renin angiotensin system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

effect of renin angiotensin inhibitors in CKD

A

decrease progression of albuminuria
decrease progression of GFR decline
decrease risk of ESRD

the beneficial effects of them are independent of BP and blood glucose control

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what do you want to avoid with tx for CKD?

A

NSAIDs-they damage the kidneys further. may interact with ACEi and ARBs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

CKD mainly causes hypo or hypercalcemia?

A

hypo, but can have hypo or hypercalcemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

plasma calcium is regulated by

A

PTH, calcitonin, calcitriol (active vit D)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

kidney failure-what happens to phosphate and calcitriol?

A

decreased GFR leads to decreased renal excretion of phosphate and diminished production of calcitriol, both leading to decreased Ca in blood and increased PTH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what leads to increase in PTH in secondary hyperparathyroidism in kidney disease?

A

decreased production of vit D3 (calcitriol)
decreased serum Ca
increased serum phosphorous

the above 3 are due to decrease in kidney fxn associated w chronic kidney dis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

MOA of calcitriol and vit D analogs

A

enhance absorption of Ca and PO4 from intestine (by increasing synthesis of Ca ch and a carrier calcium binding protein)

calcitriol also enhances recruitment and differentiation of osteoclast precursor for remodeling–resorption of Ca and PO4 from bone

also enhances tubular reabsorption of Ca

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

adverse effect of calcitriol and vit D analogs

A

excessive dosing leads to hypercalcemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

phosphate binders

A

react with phosphate in GI tract and form an insoluble compound

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

when can hypercalcemia occur?

A

with prolonged kidney disease

renal transplant pts can have parathyroid hyperplasia and then, restoration of renal fxn and calcitriol production can lead to hypercalcemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what can be used to treat hypercalcemia?

A

bisphosphonates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

bisphosphonates MOA

A

pyrophosphate analogues that bind to hydroxyapatite crystals in bone matrix to inhibit bone resorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

calcitonin MOA

A

lowers plasma Ca by limiting bone resorption

increases phosphate excretion in urine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

side effects of calcitonin

A

facial flushing
headache, dizziness
GI
taste disturbance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

rasburicase

A

I.V.
recombinant version of enzyme urate oxidase

primarily used as PROPHYLAXIS during chemo (can be used in CKD)

20
Q

calcitonin effect on kidney

A

increases Ca and PO4 excretion

21
Q

PTH effect on kidney

A

increases calcitriol and increases Ca reabsoprtion

22
Q

calcineurin inhibitors ex

A

cyclosporine

tacrolimus

23
Q

MOA of calcineurin inhibitors

A

bind to cytosolic receptor proteins

cyclophilin (cyclosporine)
FKBP12 (tacrolimus)

complex binds to and inhibits action of calcineurin

inhibits transcription of cytokines such as IL-2 that are essential for T cell activation and proliferation

24
Q

cyclosporine

A

binds cyclophilin, calcineurin inhibitor

oral or IV

25
side effects of cyclosporine
nephrotoxic hirsutism HTN and fluid retention others
26
drug interactions of cyclosporine
nephrotoxic-NSAIDs, aminoglycosides CYP3A4 inducers CYP450 inhibitors
27
tacrolimus
bind FKBP12, calcineurin inhibitor oral or IV doesn't stimulate TGFbeta (doesn't have excessive vasoconstriction) like cyclosporine does
28
side effects of tacrolimus
pleural and pericardial effusions cardiomyopathy in children glucose intolerance
29
monitoring calcineurin inhibitor side effects
hepatotoxicity--liver fxn should be monitored regularly cardiovascular (HTN, hypercholesterolemia)--fewer tacrolimus treated pts need antiHTN meds, and tacrolimus' effect on lipid levels is less than that seen with cyclosporine glucose intolerance neurotoxicity (more often w tacrolimus)
30
calcineurin inhibitor drugs interactions
nephrotoxic agents (NSAIDs, some antibiotics)--monitor renal fxn K sparing diuretics (hyperkalemia has been seen) antacids (may inhibit absorption of calcineurin inhibitors) statins (increased risk of rhabdomyolysis, bone marrow suppression)
31
use of calcineurin inhibitors has been more in favor of
tacrolimus, b/c of cyclosporine's side effects
32
sirolimus MOA
binds to FKBP12 (different site than tacromlimus). the complex binds and modulates the activity of mTOR. inhibits cytokine/IL2-induced cell cycle progression from G1 to S phase
33
sirolimus route of administration
oral
34
sirolimus side effects
edema, ascites, tachycardia, HTN hyperlipidemia bone marrow suppression others drug interactions--drugs that induce cyp3A4, drugs that inhibit CYP450
35
benefits of mTOR inhibitor sirolimus
potent prophylaxis against acute cellular rejection less vasoconstriction (than cyclosporine) not associated w acute or chronic renal insufficiency (tacrolimus and sirolimus can cause decline in kidney fxn)
36
mycophenolate mofetil
competitive, reversible inhibition of IMPDH, a critical rate limiting enzyme in de novo purine synthesis. lymphocytes are dependent on de novo pathway vs. salavage pathway utilized by other cell types. inhibits proliferation of B and T lymphocytes oral or IV
37
side effects of mycophenolate mofetil
leucopenia, thrombocytopenia, anemia opportunitistic infec others
38
azathioprine
purine analogue metabolized in liver to 6-mercaptupurine and then to thiosinosine monophosphate (TIMP) TMP decreases synthesis of DNA precursors and also incorporates into DNA more non-specific effects than mycophenolate mofetil blocks CD28 co stimulation of T cells oral
39
side effects of azathioprine
bone marrow suppression, leukopenia, thrombocytopenia
40
comparison of side effects of azathioprine and mycophenolate mofetil
both need to monitor complete blood counts. GI side effects are more common in mycophenolate mofetil
41
IL-2 receptor antibodies
basiliximab daclizumab alemtuzumab all are antiCD52-IL2 receptor antibodies
42
basiliximab
IV | given immediately prior to surgery and 4 days following
43
belatacept
IV fusion protein binds CD80 and CD 86 mkolecules. blocks costimulatory action with CD28 on T cell activation used for renal transplantation in pts SEROPOSITIVE FOR EBSTEIN BARR VIRUS
44
prednisolone
oral | inhibits pro inflammatory transcription factors such as NFkB. other mechanisms too.
45
induction agents ex
monoclonal or polycloncal antibodies given IV immediately after surgery ``` muromonab antithymocyte globulin basiliximab daclizumab alemtuzumab FTY720 ```